← Jazz Pharmaceuticals plc
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1.5b | $1.6b | $1.9b | $2.2b | $2.4b | $3.1b | $3.7b | $3.8b | $4.1b | $4.3b | |
| Operating Expenses | $896.3m | $1.1b | $1.3b | — | — | — | — | — | — | — | |
| Operating Income (Loss) | $591.7m | $528.8m | $614.8m | $532.4m | $378.1m | $170.3m | ($65.5m) | $578.6m | $716.6m | ($430.2m) | |
| Additional Financial Items | |||||||||||
| Amortization of Intangible Assets | $102.0m | $152.1m | $201.5m | $354.8m | $259.6m | $525.8m | $599.2m | $608.3m | $627.3m | $654.7m | |
| Foreign Currency Transaction Gain (Loss), before Tax | $3.4m | ($10.0m) | ($6.9m) | ($5.8m) | ($3.3m) | ($4.3m) | ($19.0m) | $8.8m | ($8.2m) | ($2.6m) | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | $179.6m | $77.5m | $170.7m | ($6.5m) | ($102.3m) | $97.6m | ($50.3m) | $449.2m | $497.9m | $164.7m | |
| Income (Loss) from Equity Method Investments | ($379k) | ($1.0m) | ($2.2m) | ($4.1m) | ($3.0m) | ($714k) | ($9.9m) | ($3.0m) | ($1.7m) | ($732k) | |
| Net Income (Loss) Attributable to Parent | $396.8m | $487.8m | $447.1m | $523.4m | $238.6m | ($329.7m) | ($224.1m) | $414.8m | $560.1m | ($356.1m) | |
| Net Income (Loss) Attributable to Noncontrolling Interest | $0 | $0 | — | — | — | — | — | — | — | — | |
| Earnings Per Share, Basic | $6.56 | $8.13 | $7.45 | $9.22 | $4.28 | ($5.52) | ($3.58) | $6.55 | $9.06 | ($5.84) | |
| Earnings Per Share, Diluted | $6.41 | $7.96 | $7.30 | $9.09 | $4.22 | ($5.52) | ($3.58) | $6.10 | $8.65 | ($5.84) | |
| Weighted Average Number of Shares Outstanding, Basic | 60.5m | 60.0m | 60.0m | 56.7m | 55.7m | 59.7m | 62.5m | 63.3m | 61.8m | 61.0m | |
| Weighted Average Number of Shares Outstanding, Diluted | 61.9m | 61.3m | 61.2m | 57.5m | 56.5m | 59.7m | 62.5m | 72.1m | 66.0m | 61.0m | |
| Research and Development Expense | $162.3m | $198.4m | $226.6m | $299.7m | — | — | — | — | — | — | |
| Selling, General and Administrative Expense | $502.9m | $544.2m | $683.5m | $736.9m | $854.2m | $1.5b | $1.4b | $1.3b | $1.4b | $1.8b | |
| Costs and Expenses | — | — | — | $1.6b | $2.0b | $2.9b | $3.7b | $3.3b | $3.4b | $4.7b | |
| Current Income Tax Expense (Benefit) | $176.4m | $177.9m | $169.0m | $163.5m | $170.5m | $146.9m | $133.6m | $140.3m | $116.9m | $172.5m | |
| Interest Expense, Debt | — | $37.8m | $56.7m | $59.1m | $76.1m | $89.9m | $32.8m | $32.8m | — | — | |
| Income Tax Expense (Benefit) | $135.2m | ($47.7m) | $80.2m | ($73.2m) | $33.5m | $216.1m | ($158.6m) | ($119.9m) | ($91.4m) | ($272.4m) | |
| Interest Income (Expense), Nonoperating, Net | ($61.9m) | ($77.8m) | ($77.1m) | ($72.3m) | ($99.7m) | ($278.8m) | ($288.2m) | ($289.4m) | ($238.1m) | ($195.1m) |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.